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Sample extraction method development and optimization SPE is used as a clean-up to remove endogenous substances from biological matrices, which may affect the analysis. Recoveries were determined by using different cartridges and solvents (MeOH or ACN), as protein precipitants. The best recoveries were achieved using the Discovery® DSC-PS/DVB SPE C 18 (100 mg, 1 mL) and MeOH for plasma and Supel™ -Select HLB (30 mg, 1 mL) and ACN for brain homogenate. Linearity Three calibration curves were constructed from each biological matrix (plasma and brain) and repeated on three consecutive days. The regression equations were y = 0.4246x + 0.0017 (r 2 = 0.9992) for EFV, y = 0.2441x + 0.0217 (r 2 = 0.9983) for TFV and y = 0.3864x − 0.0045 (r 2 = 0.9996) for FTC in SD rat plasma. Same procedure was repeated for brain homogenate matrix and the regression equations were y = 0.3025x + 0.0486 (r 2 = 0.9986), y = 0.52031x + 0.0114 (r 2 = 0.9990) and y = 0.40254x − 0.0182 (r 2 = 0.9979) in SD rat brain. All the r 2 values were above 0.99, indicating good linearity.
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Matrix effect and extraction recovery
Matrix effect was tested for six different lots of drug-free rat plasma and brain homogenates. The matrix effect for each lot was evaluated at LQC, MQC, and HQC (n = 6). According to EMA guidelines, the variability of matrix factor should be within ± 15 %. The extraction recovery of each drug was determined by comparing the peak area from the extracted samples with the peak area from un-extracted samples. Intra-day and inter-day accuracy and precision in both plasma and brain was within the limits set by EMA. See Tables S3A-C below. 
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Pharmacokinetics and statistical calculations were computed using Stata 13 (StataCorp, College Station, TX). Table S4 and Table S5 show the calculated pharmacokinetic parameters in plasma and brain, respectively. 
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Mass spectrometry imaging (MSI)
The MALDI-MS method was optimized for the detection of the three compounds by spotting freshly prepared standards on a ground steel MALDI target plate and then on an untreated brain tissue section. Figure S4 shows the imaged standard spots of each drug from the untreated brain tissues. Figure S3 . MALDI-MS spectrum for EFV (m/z 316.673) in brain tissue.
The MALDI-MS spectra for EFV (m/z 316.673), TFV (m/z 288.121) and FTC (m/z 248.463) in brain tissues are shown in Figure S4 , S5, and S6 respectively. S13 Figure S4 . MALDI-MS spectrum for EFV (m/z 316.673) in brain tissue. Figure S5 . MALDI-MS spectrum for TFV (m/z 288.121) in brain tissue. S14 Figure S6 . MALDI-MS spectrum for FTC (m/z 248.463) in brain tissue.
LIFT MS/MS confirmation
The precursor ions monitored for MS imaging were confirmed by LIFT MS/MS fragmentation and the resultant product ions are shown in Table S6 below. 
